Study Title: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, John Kaczmar, at kaczmar@musc.edu, or please call +1 843-792-6691.Study Coordinator, Madison Avinger, at avingerm@musc.edu.Trial opened at the following institutions: Medical University of South Carolina